InspireMD, Inc. Series B Warrants
NSPRZ
NSPRZ was delisted on the 14th of March, 2022.
4 hedge funds and large institutions have $8.85K invested in InspireMD, Inc. Series B Warrants in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 2 closing their positions.
20% less funds holding
Funds holding: 5 → 4 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
75% less capital invested
Capital invested by funds: $36K → $8.85K (-$27.1K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.17K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1K |
NSPRZ Hedge Fund Activity: Q2 2019 in Review
4 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in InspireMD, Inc. Series B Warrants (NSPRZ) for Q2 2019, worth a combined $8.85K — down 75% from $36K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of NSPRZ and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $2.17K. The largest seller was Sabby Management, exiting entirely with an estimated $1K sold.
- 4 institutional investors held InspireMD, Inc. Series B Warrants (NSPRZ) as of Q2 2019, down from 5 in Q1 2019.
- Funds reported $8.85K of InspireMD, Inc. Series B Warrants stock for Q2 2019, down 75% quarter-over-quarter.
- 1 fund opened new InspireMD, Inc. Series B Warrants positions in Q2 2019 and 2 closed out, a net change of -1 holder.
- The largest InspireMD, Inc. Series B Warrants buyer in Q2 2019 was Susquehanna International Group, an estimated $2.17K added.
- The largest InspireMD, Inc. Series B Warrants seller in Q2 2019 was Sabby Management, an estimated $1K sold.
Based on aggregated 13F filings for Q2 2019.